Cellular Senescence and Senotherapeutics

Cellular senescence was once considered “the end” – a point where cultured somatic cells simply stopped proliferating. The recent recognition of senescence as a central mechanism underlying aging and the development of age-associated disorders has given rise to senotherapeutics, a class of therapies dedicated to targeting cellular senescence and either eliminating senescent cells or modifying their senescence-associated secretory phenotype (SASP), the pro-inflammatory factors they secrete. Because the accumulation of senescent cells contributes to tissue dysfunction, chronic inflammation, and age-related diseases, emerging anti-aging and regenerative medicine strategies are evolving into precision senescence medicine and taking aim at cellular senescence to enhance human healthspan.

Mechanisms and Benefits

Research on senotherapeutics is ongoing, with preclinical and early clinical studies demonstrating promising results in animal models and some human trials. Senolytic and senomorphic compounds are being explored for their potential to treat frailty, metabolic disorders, and other age-related conditions. The field represents an innovative approach in anti-aging medicine and regenerative therapies. These emerging therapies are aimed at targeting senescent cells to mitigate aging effects and treat age-related diseases, with senolytics, senomorphics, and immune-based strategies forming the core approaches.

Senotherapeutics work by either eliminating senescent cells or modifying their harmful secretions, which can:

Research and Precision Senescence Medicine

As research advances, scientists are recognizing that senescent cells are not a single, uniform population. Their characteristics and effects can vary depending on the cell type, tissue, trigger, and stage of senescence. This heterogeneity is helping drive interest in precision approaches that can identify specific senescent cell populations and determine when and how they should be targeted, rather than relying on broad-spectrum approaches alone.

Scientists know that brain white matter undergoes structural and functional alterations linked to late-life cognitive decline, but the cellular and molecular basis of its selective vulnerability remains incompletely defined. Single-cell spatial trajectory analyses suggest that multiple cell fate transitions may give rise to this aged, proinflammatory, senescent- and disease-associated microglia (DAM)-linked state.

In a recent study at the Schafer Lab at UMass Chan Medical School, researchers demonstrated in naturally aged mice that senescent and DAM phenotypes converge in hippocampal-adjacent white matter, particularly in the fimbria.

Using regional gene expression profiling, immunolabeling, GeoMx digital spatial profiling, and CosMx spatial molecular imaging, they identified an aged brain-exclusive microglial population concentrated in white matter that expresses DAM genes together with a ‘SenBrain’ senescence gene signature, including galectin-3 (GAL3/Lgals3). Pharmacogenetic or pharmacological senotherapeutic interventions reduced white matter GAL3+ DAM abundance and restored a more youthful microglial organization in aged fimbria. These findings identified a senescence- and DAM-enriched microglial state as a prominent and partially reversible feature of aged brain white matter, suggesting that targeting specific senescent cell populations may eventually offer new strategies for addressing age-related brain dysfunction.

Types of Senotherapeutics

Senolytics: These agents selectively induce apoptosis in senescent cells, effectively removing them from tissues. Examples include dasatinib and quercetin, which have shown efficacy in reducing senescent cell burden in animal models and improving healthspan.

Senomorphics (Senostatics): These compounds modulate the function of senescent cells without killing them, often by inhibiting SASP to reduce inflammation and tissue damage. They can also delay the progression of younger cells into senescence.

Immune-mediated senotherapeutics: These strategies enhance the immune system’s ability to clear senescent cells, which is particularly important as immune function declines with age.

Concluding Thoughts

The involvement of cellular senescence in disease and aging is increasingly well established, and the elimination of senescent cells as a strategy for treating age-related diseases has emerged as a promising path forward. The development of senolytic drugs has already demonstrated that targeting these cells can help address deterioration, even as first-generation senolytics have demonstrated limitations during clinical development. As current research shifts toward precision senotherapy, significant challenges remain, but the strategy of targeting senescent cells to fight disease and decline and enhance healthspan continues to evolve.

Sources:

Senolytics: From Pharmacological Inhibitors to Immunotherapies, a Promising Future for Patients' Treatment 

Senotherapeutics: Emerging Strategy for Healthy Aging and Age-Related Disease

Spatial Mapping and Senolytic Targeting of Senescent and Disease-Associated Microglia in Aged Mouse Brain White Matter 

Emerging Strategies in Senotherapeutics: From Broad-Spectrum Senolysis to Precision Reprogramming